RxDoctor Payments Data

James Bullock, MD

Family Medicine · New Albany, MSNPI 1346747953

Payments from drug & device makers

$8,188in general payments, 2019–2025

Across 565 payments — averaging $14.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$827
  • GSK$766
  • Pfizer$691
  • Stryker$645
  • Lilly USA, LLC$465
  • plus $4K from 36 others

What the payments were for

  • Travel & lodging$3354%
  • Food & beverage$7,85396%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,188 in reported general payments places this provider in the 90th percentile of 971 family medicine providers in Mississippi.

See all family medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$137,842
Medicare patients
453
Services billed
2,343

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol78$72,132
JardianceEmpagliflozin79$69,937
EliquisApixaban95$65,534
MounjaroTirzepatide49$64,135
Trelegy ElliptaFluticasone/Umeclidin/Vilanter84$63,148
OzempicSemaglutide34$46,255
LinzessLinaclotide52$36,710
TradjentaLinagliptin30$21,228
UbrelvyUbrogepant13$20,960
VraylarCariprazine Hcl14$19,870
EntrestoSacubitril/Valsartan24$15,572
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$13,029
XareltoRivaroxaban15$12,663
Tresiba Flextouch U-200Insulin Degludec15$10,156
Soliqua 100-33Insulin Glargine/Lixisenatide11$8,667

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$242$91,165109 claims
AstraZenecaFarxiga, Breztri Aerosphere$827$85,16199 claims
AbbVieLinzess, Ubrelvy, Vraylar$1,270$77,53979 claims
PfizerEliquis$691$65,53495 claims
Lilly USA, LLCMounjaro$465$64,13549 claims
GSKTrelegy Ellipta$766$63,14884 claims
Novo NordiskOzempic$397$46,25534 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$102$8,66711 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$103$8,12511 claims
Astellas Pharma US IncMyrbetriq$53$7,81413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 971 family medicine providers in Mississippi.

Other family medicine in New Albany

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →